Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2017;52:811–7. https://doi.org/10.1038/bmt.2017.34.
Wang Y, Chen H, Chen J, Han M, Hu J, Jiong H, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett. 2018;438:63–75. https://doi.org/10.1016/j.canlet.2018.08.030.
Filippini Velazquez G, Labopin M, Tischer J, Raiola AM, Angelucci E, Kulagin AD, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2023;58:907–15. https://doi.org/10.1038/s41409-023-01985-7.
Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259–71. https://doi.org/10.1200/JCO.2012.44.7961.
Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kroger N, et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J. 2019;9:88. https://doi.org/10.1038/s41408-019-0251-3.
Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245–53. https://doi.org/10.1001/jamaoncol.2018.2091.
Wu H, Shi J, Luo Y, Yu J, Lai X, Liu L, et al. Assessment of patient-specific human leukocyte antigen genomic loss at relapse after antithymocyte globulin-based T-cell-replete haploidentical hematopoietic stem cell transplant. JAMA Netw Open. 2022;5:e226114 https://doi.org/10.1001/jamanetworkopen.2022.6114.
Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29:1143–52. https://doi.org/10.1038/leu.2014.314.
Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88. https://doi.org/10.1056/NEJMoa0811036.
McCurdy SR, Iglehart BS, Batista DA, Gocke CD, Ning Y, Knaus HA, et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016;30:2102–6. https://doi.org/10.1038/leu.2016.144.
Zhang T, Zhang Y, Zhou M, Zhang Z, Bao X, Wen L, et al. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024;204:1402–13. https://doi.org/10.1111/bjh.19304.
Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, et al. Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. Biol Blood Marrow Transpl. 2017;23:1887–94. https://doi.org/10.1016/j.bbmt.2017.07.014.
Vago L, Ciceri F. Choosing the alternative. Biol Blood Marrow Transpl. 2017;23:1813–4. https://doi.org/10.1016/j.bbmt.2017.09.009.
Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kruger K, Teich K, et al. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood. 2024;144:296–307. https://doi.org/10.1182/blood.2023022697.
Vago L, Toffalori C, Ahci M, Lange V, Lang K, Todaro S, et al. Incidence of HLA loss in a global multicentric cohort of post-transplantation relapses: results from the hlaloss collaborative study. Blood. 2018;132:818–818. https://doi.org/10.1182/blood-2018-99-112142.
Villalobos IB, Takahashi Y, Akatsuka Y, Muramatsu H, Nishio N, Hama A, et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood. 2010;115:3158–61. https://doi.org/10.1182/blood-2009-11-254284.